ALLO - Allogene Therapeutics, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 962.16M
Enterprise value 590.64M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)4.06k
Price/book (mrq)1.63
Enterprise value/revenue 2.52k
Enterprise value/EBITDA -1.74

Trading information

Stock price history

Beta (5Y monthly) 0.77
52-week change 3-30.48%
S&P500 52-week change 33.90%
52-week high 317.49
52-week low 34.42
50-day moving average 35.46
200-day moving average 38.26

Share statistics

Avg vol (3-month) 32.02M
Avg vol (10-day) 31.63M
Shares outstanding 5145.84M
Implied shares outstanding 6N/A
Float 884.75M
% held by insiders 129.16%
% held by institutions 178.32%
Shares short (14 May 2023) 440.59M
Short ratio (14 May 2023) 416.77
Short % of float (14 May 2023) 444.19%
Short % of shares outstanding (14 May 2023) 427.83%
Shares short (prior month 13 Apr 2023) 441.22M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-151,507.26%

Management effectiveness

Return on assets (ttm)-25.89%
Return on equity (ttm)-48.56%

Income statement

Revenue (ttm)234k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-14.80%
Gross profit (ttm)243k
EBITDA -340.42M
Net income avi to common (ttm)-351.49M
Diluted EPS (ttm)-2.50
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)471.22M
Total cash per share (mrq)3.23
Total debt (mrq)99.7M
Total debt/equity (mrq)16.83
Current ratio (mrq)8.08
Book value per share (mrq)4.06

Cash flow statement

Operating cash flow (ttm)-218.92M
Levered free cash flow (ttm)-101.18M